MUCOSAL EOSINOPHILS AS MARKERS OF POST- INDUCTION VEDOLIZUMAB RESPONSE IN PAEDIATRIC ULCERATIVE COLITIS

被引：0

作者：

Musto, F. ^{[1
]}

Ranalli, M. ^{[1
]}

Giordano, C. ^{[1
]}

Bianchi, E. ^{[1
]}

Veraldi, S. ^{[1
]}

Oliva, S. ^{[1
]}

D'Arcangelo, G. ^{[1
]}

Aloi, M. ^{[1
]}

机构：

[1] Sapienza Univ, Rome, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OC.14.5

引用

页码：S126 / S126

页数：1

共 50 条

[21] Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation
Van den Berghe, N.
Verstockt, B.
Gils, A.
Ferrante, M.
Vermeire, S.
Thomas, D.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S411 - S412
[22] Mucosal Healing with Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium
Kochhar, Gursimran
Parikh, Malav
Chaudrey, Khadija
Shmidt, Eugenia
Luo, Michelle
Barocas, Morris
Boland, Brigid
Singh, Siddharth
Hudesman, David
Swaminath, Arun
Lukin, Dana
Sands, Bruce
Colombel, Jean-Frederic
Sandborn, William
Siegel, Corey
Loftus, Edward, Jr.
Kane, Sunanda
Shen, Bo
Dulai, Parambir
INFLAMMATORY BOWEL DISEASES, 2017, 23 : S6 - S6
[23] Interleukin-8 mucosal transcript as predictor of response to Vedolizumab treatment in Ulcerative Colitis: preliminary results from a prospective study
Bota, A. D.
Musa, A. M.
Dinu, M. C.
Saftoiu, A.
Musa, M.
Coman, S.
Dobre, M.
Milanesi, E.
Tieranu, C. G.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I329 - I329
[24] Real World Evidence of Vedolizumab Achieving Mucosal Healing and Endoscopic Improvement in Patients With Ulcerative Colitis
Shaw, Caroline
Brown, Rebecca
Wang, Song
Adsul, Shashi
Agboton, Christian
Kamble, Pravin
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S344 - S345
[25] Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders
Feagan, B.
Sandborn, W. J.
Smyth, M.
Sankoh, S.
Parikh, A.
Fox, I.
JOURNAL OF CROHNS & COLITIS, 2014, 8 : S276 - S277
[26] Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment
Zezos, P.
Kabakchiev, B.
Weizman, A. V.
Nguyen, G. C.
Narula, N.
Croitoru, K.
Steinhart, A. H.
Silverberg, M. S.
JOURNAL OF CROHNS & COLITIS, 2017, 11 : S334 - S335
[27] ULCERATIVE COLITIS PATIENTS ON VEDOLIZUMAB LACKING RESPONSE AT INDUCTION PHASE CONTINUE TO IMPROVE OVER THE FIRST 6 MONTHS OF TREATMENT
Zezos, Petros
Kabakchiev, Boyko
Weizman, Adam
Nguyen, Geoffrey C.
Narula, Neeraj
Croitoru, Kenneth
Steinhart, A. Hillary
Silverberg, Mark S.
GASTROENTEROLOGY, 2017, 152 (05) : S400 - S401
[28] Effects of Continued Vedolizumab Therapy for Ulcerative Colitis in Week 6 Induction Therapy Nonresponders
Feagan, Brian G.
Sandborn, William
Smyth, Michael D.
Sankoh, Serap
Parikh, Asit
Fox, Irving
GASTROENTEROLOGY, 2014, 146 (05) : S590 - S590
[29] Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis
Courtney Perry
Kyle Fischer
Ahmed Elmoursi
Cody Kern
Alden Currier
Praneeth Kudaravalli
Olalekan Akanbi
Nishant Tripathi
Pradeep Yarra
Leon Su
Deborah Flomenhoft
Arnold Stromberg
Terrence A. Barrett
Digestive Diseases and Sciences, 2021, 66 : 2051 - 2058
[30] Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
Reinisch, Walter
Bressler, Brian
Curtis, Rebecca
Parikh, Asit
Yang, Huyuan
Rosario, Maria
Roseth, Arne
Danese, Silvio
Feagan, Brian
Sands, Bruce E.
Ginsburg, Philip
Dassopoulos, Themistocles
Lewis, James
Xu, Jing
Wyant, Tim
INFLAMMATORY BOWEL DISEASES, 2019, 25 (04) : 803 - 810

← 1 2 3 4 5 →